检索结果-南通市图书馆

The real-world study of the clinical characteristics,diagnosis,and treatment of advanced pancreatic cancer in china

Journal of Pancreatology 2024年第1期7卷 1-9页

作者： Jiujie Cui qihan Fu Xiaobing Chen Yanling wang qi Li Feng wang Zhihua Li Guanghai Dai Yusheng wang Hongmei Zhang Houjie Liang Jun Zhou Liu yang Fenghua wang Leizhen Zheng Xiaofeng Chen Ping Gong Jiang Liu Ying Yuan Lin wang Yuejuan Cheng Jun Zhang Yuhong Zhou Weijian Guo Xianbao Zhan Zhengyun Zou Da Li Shan Zeng Enxiao Li Zhiwei Li Zan Teng Dan Cao Jie Kan Jianping Xiong Ming Quan Jiayu Yao Haiyan yang Liwei wang department of medical Oncology Renji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghaiChina department of medical Oncology The First Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhouChina department of medical Oncology Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhouChina department of medical Oncology Shanghai General HospitalShanghai Jiao Tong UniversityShanghaiChina department of medical Oncology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina department of medical Oncology Sun Yat-sen Medical Hospital Sun Yat-sen UniversityGuangzhouChina medical Oncology Chinese PLA General HospitalBeijingChina department of Gastrointestinal Oncology Shanxi Provincial Cancer HospitalAffiliated to Shanxi Medical UniversityTaiyuanChina department of Clinical Oncology Xijing HospitalAir Force Medical UniversityXi’anChina department of Oncology and Southwest Cancer Center Southwest HospitalThird Military Medical University(Army Military Medical University)ChongqingChina department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing)Peking University Cancer Hospital&InstituteBeijingChina Cancer Center Department of Medical OncologyZhejiang Provincial People’s HospitalPeople’s Hospital of Hangzhou Medical CollegeHangzhouChina department of medical Oncology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongChina Oncology department Xin Hua Hospital Affiliated to Shanghai JiaoTong University School of MedicineShanghaiChina department of Oncology the First Affiliated Hospital with Nanjing Medical UniversityNanjingChina department of Oncology The First Affiliated HospitalSchool of MedicineShihezi UniversityShiheziChina department of Oncology People’s Hospital of Xinjiang Uygur Autonomous RegionXinjiangChina department of medical Oncology t

Objective:Real-world diagnostic and treatment data for pancreatic cancer in china are *** such,the present study investigated the clinical characteristics,diagnosis,and treatment of advanced pancreatic cancer(including locally advanced and metastatic disease)in the hospital-based Advanced Pancreatic Cancer Cohort in china of the china Pancreas Data Center ***:A total of 5349 Chinese patients with advanced pancreatic cancer were identified from a *** entire course of real-world pancreatic cancer management was ***:The proportion of patients with advanced pancreatic cancer was higher among males than females(62.4%vs 37.6%,respectively).Patients typically had a history of hypertension(30.8%),diabetes(21.6%),and cholangitis(20.2%).Abdominal pain(51.6%),abdominal distension(27.1%),jaundice(20.1%),and weight loss(16.3%)were the main symptoms observed in patients with advanced pancreatic cancer in this *** carbohydrate antigen(CA)19-9 is one of the most common tumor *** the present study,2562 patients underwent first-line *** median progression-free survival(PFS)for patients undergoing first-line therapy was 4.1 *** major options for first-line therapy included gemcitabine(GEM)plus S-1(GS/X)(23.4%),nab-paclitaxel plus GEM(AG)(18.1%),oxaliplatin,irinotecan,and leucovorin-modulated fluorouracil(FOLFIRINOX;11.9%),nab-paclitaxel plus S-1(AS)(8.9%),and GEM combined with oxaliplatin/cisplatin(GEMOX/GP)(7.6%).The AS and GS/X regimens were associated with the highest PFS ***:This is the first study to report multicenter,real-world data regarding advanced pancreatic cancer in *** revealed that real-world treatment options differed from guideline recommendations,and PFS was shorter than that in previously reported *** intelligent follow-up systems and standardizing diagnosis and treatment of pancreatic cancer is recommended.

关键词： Advanced pancreatic cancer china Pancreas Data Center Chinese First-line regimens Real-world study

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Treatment and surveillance for non-muscle-invasive bladder cancer:a clinical practice guideline(2021 edition)

引用

military medical Research 2023年第2期10卷 141-161页

作者： Ying-Hui Jin Xian-Tao Zeng Tong-Zu Liu Zhi-Ming Bai Zhong-ling Dou De-Gang Ding Zhi-Lu Fan Ping Han Yi-Ran Huang xing Huang Ming Li Xiao-Dong Li Yi-Ning Li xu-Hui Li Chao-Zhao Liang Jiu-Min Liu Hong-Shun Ma Juan qi Jia-qi Shi Jian wang De-Lin wang Zhi-Ping wang Yun-Yun wang Yong-Bo wang qiang Wei Hai-Bo Xia Jin-chun xing Si-Yu Yan xue-Pei Zhang Guo-You Zheng Nian-Zeng xing Da-Lin He xing-Huan wang on behalf of the Chinese Urological Doctor Association(CUDA),Urological Association of Chinese Research hospital Association(CRHA-UA),Uro-Health Promotive Association of china International Exchange,Promotive Association for medical,Health Care(CPAM-UHPA) Center for Evidence-Based and Translational medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China department of Urology Institute of UrologyZhongnan Hospital of Wuhan UniversityWuhan 430071China department of Urology Haikou People’s HospitalHaikou Afliated Hospital of Central South University Xiangya School of MedicineHaikou 570208China department of Urology the First Afliated Hospital and College of Clinical MedicineHenan University of Science and TechnologyLuoyang 450052HenanChina department of Urology Henan Provincial People’s Hospi-talZhengzhou University People’s HospitalZhengzhou 450003China department of Urology the Second Hospital of Dalian Medical UniversityDalian 116023LiaoningChina department of Urology Institute of UrologyWest China HospitalSichuan UniversityChengdu 610041China department of Urology Renji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200120China department of Urology the People’s Hos-pital of Xinjiang Uygur Autonomous RegionUrumqi 830002China Depart-ment of Urology Huaihe Hospital of Henan UniversityKaifeng 475000HenanChina Institutes of Evidence-Based medicine and Knowledge Translation Henan UniversityKaifeng 475000HenanChina department of Urology the Second Afliated Hospital and Second Clinical Medical College of Fujian Medical UniversityQuanzhou 362000FujianChina department of Urol-ogy the First Afliated Hospital of Anhui Medical UniversityHefei 230022China department of Urology Guangdong Provincial People’s HospitalGuangdong Academy of Medical SciencesGuangzhou 510080China department of Urology Tianjin First Central HospitalTianjin 300190China department of Urology Xinhua HospitalSchool of MedicineShanghai Jiao Tong University School of MedicineShanghai 200092China department of Urology Afliated Hospital of Guizhou Medical UniversityGuiyang 550004China department of Urology Qinghai University Afliated HospitalXining 810012China department of Urology the First Afliated Hospital of Chongqing Medical Univ

Non-muscle invasive bladder cancer(NMIBC)is a major type of bladder cancer with a high incidence worldwide,resulting in a great disease *** and surveillance are the most important part of NIMBC *** 2018,we issued“Treatment and surveillance for non-muscle-invasive bladder cancer in china:an evidencebased clinical practice guideline”.Since then,various studies on the treatment and surveillance of NMIBC have been *** is a need to incorporate these materials and also to take into account the relatively limited medical resources in primary medical institutions in *** a version of guideline which takes these two issues into account to promote the management of NMIBC is therefore *** formed a working group of clinical experts and *** questionnaire investigation of clinicians including primary medical institutions,24 clinically concerned issues,involving transurethral resection of bladder tumor(TURBT),intravesical chemotherapy and intravesical immunotherapy of NMIBC,and follow-up and surveillance of the NMIBC patients,were determined for this *** and recommendations on the management of NMIBC in databases,guideline development professional societies and monographs were referred to,and the European Association of Urology was used to assess the certainty of generated ***,we issued 29 statements,among which 22 were strong recommendations,and 7 were weak *** recommendations cover the topics of TURBT,postoperative chemotherapy after TURBT,Bacillus Calmette–Guérin(BCG)immunotherapy after TURBT,combination treatment of BCG and chemotherapy after TURBT,treatment of carcinoma in situ,radical cystectomy,treatment of NMIBC recurrence,and follow-up and *** hope these recommendations can help promote the treatment and surveillance of NMIBC in china,especially for the primary medical institutions.

关键词： Non-muscle invasive bladder cancer Bladder cancer Transurethral resection of bladder tumor Treatment Surveillance Guideline

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

laboratory Characterizations on 2007 Cases of Monoclonal Gammopathies in East china

引用

Cellular & Molecular Immunology 2008年第4期5卷 293-298页

作者： hao wang chunfang gao lingling xu zaixing yang Wenjing Zhao Xiantao Kong department of laboratory medicine Changzheng Hospital SecondMilitary Medical University Shanghai 200003 China department of laboratory medicine Eastern Hepatobiliary HospitalSecond Military Medical University. Shanghai 200438. China

Monoclonal gammopathies are characterized by the presence of monoclonal immunoglobulin in patients with or without evidence of multiple myeloma （MM）, macroglobulinemia, amyloidosis （AL）, or a related plasma cell proliferative disorder. This study aims to evaluate laboratory diagnostic characters of monoclonal gammopathies and investigates the correlation between monoclonal gammopathies and transforming growth factor β1 （TGFβ1）. Immunofixation electrophoresis （IFE）, serum protein electrophoresis （SPE）, nephelometry and urine light chain ELISA were used for laboratory identification of monoclonal immunoglobulins. Plasma TGFβ1 was detected with double-antibodies ELISA. Lightcycler was used for single nucleotide polymorphism （SNP） analysis. Totally 2,007 cases of monoclonal immunoglobulin （M protein） were identified in 10,682 samples. The isotypes of M protein were IgG type 47.1%, IgA 23.0%, IgM 8.7%, IgD 5.3%, free light chain κ 6.1%, λ 9.8%. In reference to IFE, the coherency of diagnosis was serum light chain ratio （κ/λ） 94.4%, quantitation of Igs 83%, light chain quantitation 80.9%, and urine light chain ratio （κ/λ） 58.0%. Plasma TGFβ1 was elevated significantly compared to normal control. The allelic frequency of codon 10 （C 〉 T） was neither associated with the existence of the M protein nor with the M protein isotype. Monoclonal gammopathies can be identified with the combination of IFE, SPE, Igs quantitaion and urine light chain determination. Although TGFβ1, an important cytokine in immune regulation, was elevated in monoclonal gammopathies, the SNPs in coding region of TGFβ1 gene did not confer susceptibility to the development of monoclonal gammopathies in this study. Cellular ＆ Molecular Immunology. 2008;5（4）： 293-298.

关键词： monoclonal gammopathies laboratory diagnosis TGFβ1 SNP

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

实时定量PCR检测外周血中的巨细胞病毒

引用

现代检验医学杂志 2005年第1期20卷 14-16页

作者：刘莉蔡刚张军方超平李闻捷沈茜第二军医大学附属长海医院实验诊断科上海200433

目的建立定量检测外周血中巨细胞病毒的实时定量PCR方法,并对骨髓移植病人进行巨细胞感染监测。方法构建基于LightCycler-TaqMan探针的实时定量PCR方法,对其进行方法学评价,并抽提外周血DNA,检测正常人与骨髓移植病人巨细胞病毒感染状... 详细信息

目的建立定量检测外周血中巨细胞病毒的实时定量PCR方法,并对骨髓移植病人进行巨细胞感染监测。方法构建基于LightCycler-TaqMan探针的实时定量PCR方法,对其进行方法学评价,并抽提外周血DNA,检测正常人与骨髓移植病人巨细胞病毒感染状况。结果经反应条件的优化,该方法的敏感性在10个拷贝数以上,批内与批间差异分别控制在较小范围,对骨髓移植病人巨细胞病毒感染的监测发现病毒拷贝数与病程进展和恢复呈较好的相关关系。结论实时定量PCR方法检测巨细胞病毒感染可为临床对移植患者的感染提供一种有效的监测手段。

关键词：实时定量PCR 巨细胞病毒移植

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

阿尔茨海默病的中药治疗和血脑屏障转运蛋白功能变化研究进展

引用

中国药学杂志 2018年第7期53卷 490-495页

作者：张明勇刘敏洪战英柴逸峰第二军医大学药学院药物分析学教研室上海市药物(中药)代谢产物研究重点实验室上海200433 第二军医大学长海医院药学部上海200433

阿尔茨海默病(Alzheimer's disease,AD)是一种以记忆与认知功能下降为主要临床表现的中枢神经系统疾病。中药防治AD的实验室研究和临床应用上取得了一定进展,但AD病理机制和中药治疗AD靶点仍未明确。血脑屏障(blood-brain barrier,BBB)... 详细信息

阿尔茨海默病(Alzheimer's disease,AD)是一种以记忆与认知功能下降为主要临床表现的中枢神经系统疾病。中药防治AD的实验室研究和临床应用上取得了一定进展,但AD病理机制和中药治疗AD靶点仍未明确。血脑屏障(blood-brain barrier,BBB)是维持中枢神经系统动态平衡的生理屏障,AD疾病状态下BBB损伤且转运蛋白的表达和功能异常,对脑内淀粉样蛋白的清除以及AD药物、中药活性成分跨BBB转运均产生影响。笔者对中药防治AD的研究、AD发生发展中BBB损伤、相关转运蛋白的功能变化及药物影响等进行综述,以期为开发AD治疗的新策略和新药物提供参考。

关键词：阿尔茨海默病血脑屏障转运蛋白中药

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Percutaneous Ventricular Restoration Therapy Using the Parachute Device in Chinese Patients with Ischemic Heart Failure： Three-Month Primary End-point Results of PARACHUTE china Study

引用

Chinese medical Journal 2016年第17期129卷 2058-2062页

作者： Yue-Jin yang Yong Huo Ya-Wei xu Jian-An wang Ya-ling Han Jun-Bo Ge Rui-Yan Zhang Xiao-Yan Yan Run-Lin gao department of Cardiology Fu Wai Hospital National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences Belling 100037 China department of Cardiology Peking University First Hospital Beijing 100034 China department of Cardiology Shanghai Tenth People's Hospital Tongji University Shanghai 200072 China department of Cardiology The Second Affiliated Hospital of Zhejiang University Hangzhou Zhejiang 310009 China department of Cardiology The General Hospital of Shenyang Military Region Shenyang Liaoning 110000 China department of Cardiology Fudan University Zhongshan Hospital Shanghai 200032 China department of Cardiology School of Medicine Shanghai Jiaotong University Ruijin Hospital Shanghai 200025 China department of Biostatistics Peking University Clinical Research Institute Beijing 100191 China

Background： The primary cause of ischemic heart failure （HF） is myocardial infarction （MI） resulting in left ventricle （LV） wall motion abnormality secondary to ventricular remodeling. A prospective, nonrandomized study conducted in china was designed to assess safety and efficacy of the percutaneous ventricular restoration therapy using Parachute device （CardioKinetix, lnc., CA, USA） in ischemic HF patients as a result of LV remodeling after anterior wall M1. Methods： Thirty-one patients with New York Heart Association （NYHA） Class I1, I11 ischemic HF, ejection traction between 15% and 40%, and dilated akinetic or dyskinetic anterior-apical wall without the need to be revascularized were enrolled from seven sites in china from October to December 2014. The Parachute device was implanted through femoral artery. All patients received low-dose aspirin and anticoagulation with warfarin tbr at least 12 months postdevice implantation. The primary end-point was the assessment of efficacy as measured by the reduction in LV end-systolic volume index （LVESVI） against baseline LVESVI at 3 months postdevice implantation, determined by the echocardiography and measured by echocardiography core laboratory. Quality of life was assessed using EQ-SD and visual analog scale （VAS）. For quantitative data comparison, paired t-test （normality data） and signed-rank test （abnormality data） were used： application of signed-rank test was tbr the ranked data comparison. Results： A change in LVESVI as measured by echocardiography from the preimplant baseline to 3-month postdevice implantation revealed a statistically significant reduction from 77.5 ~ 20.0 ml/m-＇ to 53,1 ~ 17.0 ml/m-＂（P 〈 0.0001 ）, The trial met its primary end-point. Of the 31 patients, the procedural success was 96.8%. Overall, NYHA HF class assessment results showed an improvement of more than halfa class at 3 months （P 〈 0.001 ）. Quality of life assessed by the VAS value increased 11.5 points （P 〈 0.01 ）, demonstrating im

关键词： lschemic Heart Failure Left Ventricle Remodeling Percutaneous Ventricular Restoration Structural Heart

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

One-year status of hepatic venous pressure gradient measurement from 85 hospitals in china

引用

Portal Hypertension & Cirrhosis 2024年第2期3卷 116-123页

作者： Jitao wang Ting Cui Linpeng Zhang Zhiping Yan Lei Li Jinjun Chen Junhui Sun Hua Xiang He Zhu hao Wu Jiancuo Gengzang Feng Zhang Wei Wu Guohong Cao Wuhua Guo Haibin Shi Hui xue Guangjun Huang qiang Yu Meng Niu Huiling Xiang Derun Kong Wei Gou xuefeng Luo Fuliang He Min Yuan Wei Liu Yong wang Hongjie Hu Xiaoli Zhu Tao Yu qinxue Sun Wei Qu Ting Lu Deqiang Ma Li Zhang Jun Ma Jun yang Ketao Mu Xiaoliang Zhu Kai Xiong Huiguo Ding Shengjuan Yao Mingsheng Huang fang wang Zexin wang Yong Huang Jianan Li Hongfeng Yi Birun Huang Zhongwei Zhao Duiping Feng Yanming Lei Changlong Hou Wenbo Guo Shirong Liu gaojun Teng Kangshun Zhu Fan Wu Xiaogang Hu Wenfeng Zhang Shaoqi yang Zhouchao Hu pengfei Pang Shaowu Zhuang Weidong wang qingliang Zhu Kunpeng Zhang Chengyu Liu Dongliang Li Chao Ma Hong Jiang xingong Zhao Weixin Ren Zhiwei wang Lei Yu Fuhuang Lin Chaoguang Yan Feng wang Lei Yu Hui Huan Wenyong Shen Shaofei He Chengda Zhang Jinlun Bao Jiangtao Liu Jun Wu Jianbo Zhao Jian Zhang Xiaolong qi Hebei Provincial Key laboratory of Cirrhosis&Portal Hypertension Xingtai People's HospitalXingtaiHebeiChina Center of Portal Hypertension Department of RadiologyZhongda HospitalSchool of MedicineSoutheast UniversityNanjingJiangsuChina department of Interventional Therapy Beijing Shijitan Hospital Affiliated to Capital Medical UniversityBeijingChina department of Intervention Taiyuan Third People's HospitalTaiyuanShanxiChina department of Intervention Zhongshan Hospital Affiliated to Fudan UniversityShanghaiChina department of Interventional medicine The First Hospital of Lanzhou UniversityLanzhouGansuChina department of Infectious Diseases Nanfang Hospital of Southern Medical UniversityGuangzhouGuangdongChina hepatobiliary and Pancreatic Intervention Center The First Affiliated Hospital of Zhejiang University School of MedicineHangzhouZhejiangChina Interventional Vascular Surgery Hunan Provincial People's HospitalChangshaHunanChina department of Intervention Sixth People's Hospital of ShenyangShenyangLiaoningChina department of Gastroenterology West China Hospital of Sichuan UniversityChengduSichuanChina department of Intervention The Fourth People's Hospital of Qinghai ProvinceXiningQinghaiChina department of Gastroenterology Nanjing Drum Tower HospitalNanjingJiangsuChina department of Gastroenterology The First Affiliated Hospital of Wenzhou Medical UniversityWenzhouZhejiangChina department of Radiology Shulan(Hangzhou)HospitalHangzhouZhejiangChina department of Intervention Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhouFujianChina department of Interventional Radiology The First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsuChina department of Gastroenterology The First Affiliated Hospital of Xi'an Jiaotong UniversityXi'anShaanxiChina department of Gastroenterology Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityJinanShandongChina department of Interventional Radiology Fifth Medical Center

Aims:Surveys and research on the applications of the hepatic venous pressure gradient(HVPG)are important for understanding the current status and future development of this technology in *** article aimed to investigate the status of hepatic venous pressure gradient measurement in china in ***:We investigated the overall status of HVPG technology in china-including hospital distribution,hospital level,annual number of cases,catheters used,average cost,indications,and current challenges by using online *** counting the number and percentages of cases of these results,we hope to clarify the current status of HVPG measurements in ***:According to the survey,85 hospitals in china used HVPG technology in 2022 distributed across 29 provinces.A total of 4989 HVPG measurements were performed in all of the surveyed hospitals in 2022,of which 2813 cases(56.4%)were measured *** average cost of HVPG measurement was 5646.8±2327.9 *** the clinical teams who performed the measurements(sometimes multiple per hospital),94.3%(82/87)used the balloon method,and the majority of the teams(72.4%,63/87)used embolectomy ***:This survey clarified the clinical application status of HVPG in china and confirmed that some medical institutions in china have established a foundation for this *** is still necessary to continue promoting and popularizing this technology in the future.

关键词： application status hepatic vein pressure gradient questionnaire survey

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Consensus on the digestive endoscopic tunnel technique

引用

World Journal of Gastroenterology 2019年第7期25卷 744-776页

作者： Ning-Li Chai Hui-Kai Li En-qiang linghu Zhao-Shen Li Shu-Tian Zhang Yu Bao Wei-Gang Chen Philip WY Chiu Tong Dang Wei Gong Shu-Tang Han Jian-Yu hao Shui-Xiang He Bing Hu1 Bing Hu2 Xiao-Jun Huang Yong-Hui Huang Zhen-Dong Jin Mouen A Khashab James Lau peng Li Rui Li De-Liang Liu Hai-Feng Liu Jun Liu Xiao-Gang Liu Zhi-Guo Liu Ying-Cai Ma Gui-Yong peng Long Rong Wei-Hong Sha Pateek Sharma Jian-qiu Sheng Shui-Sheng Shi Dong Wan Seo Si-Yu Sun Gui-qi wang Wen wang qi Wu Hong xu Mei-Dong xu Ai-Ming yang fang Yao Hong-Gang Yu Ping-Hong Zhou Bin Zhang Xiao-Feng Zhang Ya-qi Zhai department of Gastroenterology and Hepatology Chinese PLA General HospitalBeijing 100853China department of Gastroenterology Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China department of Gastroenterology the First Affiliated Hospital of Xi’an Jiao Tong UniversityXi’an 710000Shaanxi ProvinceChina department of Gastroenterology West China HospitalSichuan UniversityChengdu 610041Sichuan ProvinceChina department of Endoscopy Eastern Hepatobiliary Surgical Hospital Affiliated to Naval Medical UniversityShanghai 200438China department of Gastroenterology the Second Hospital of Lanzhou UniversityLanzhou 730030Gansu ProvinceChina department of Gastroenterology Peking University Third HospitalBeijing 100191China Division of Gastroenterology and Hepatology the Johns Hopkins University School of MedicineBaltimoreMD 21218United States department of Gastrointestinal Endoscopy Prince of Wales Hospitalthe Chinese University of Hong KongHong KongChina department of Gastroenterology the First Affiliated Hospital of Soochow UniversitySuzhou 215006Jiangsu ProvinceChina department of Gastroenterology Second Xiangya Hospital of Central South UniversityChangsha 410000Hunan ProvinceChina department of Gastroenterology Changhai HospitalNaval Medical UniversityShanghai 200433China department of Gastroenterology General Hospital of Chinese People’s Armed Police ForcesBeijing 100039China Division of Gastroenterology Union Hospital of Tongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022Hubei ProvinceChina department of Gastroenterology Sichuan Provincial People’s HospitalChengdu 610072Sichuan ProvinceChina department of Gastroenterology Xijing HospitalAir Force Medical UniversityXi’an 710032Shaanxi ProvinceChina department of Digestion Qinghai Provincial People’s HospitalXining 810007Qinghai ProvinceChina department of Gastroenterology Southwest HospitalArmy Medical UniversityChongqing 400038China department of Gastroenterology Peking Univ

With the digestive endoscopic tunnel technique(DETT), many diseases that previously would have been treated by surgery are now endoscopically curable by establishing a submucosal tunnel between the mucosa and muscularis propria(MP). Through the tunnel, endoscopic diagnosis or treatment is performed for lesions in the mucosa, in the MP, and even outside the gastrointestinal(GI) *** present, the tunnel technique application range covers the following:(1)Treatment of lesions originating from the mucosal layer, e.g., endoscopic submucosal tunnel dissection for oesophageal large or circular early-stage cancer or precancerosis;(2) treatment of lesions from the MP layer, per-oral endoscopic myotomy, submucosal tunnelling endoscopic resection, etc.; and(3) diagnosis and treatment of lesions outside the GI tract, such as resection of lymph nodes and benign tumour excision in the mediastinum or abdominal cavity. With the increasing number of DETTs performed worldwide, endoscopic tunnel therapeutics, which is based on DETT, has been gradually developed and optimized. However, there is not yet an expert consensus on DETT to regulate its indications, contraindications, surgical procedure, and postoperative *** International DETT Alliance signed up this consensus to standardize the procedures of DETT. In this consensus, we describe the definition, mechanism,and significance of DETT, prevention of infection and concepts of DETTassociated complications, methods to establish a submucosal tunnel, and application of DETT for lesions in the mucosa, in the MP and outside the GI tract(indications and contraindications, procedures, pre-and postoperative treatments, effectiveness, complications and treatments, and a comparison between DETT and other operations).

关键词： Digestive endoscopic tunnel technique Endoscopic submucosal tunnel dissection Per-oral endoscopic myotomy Submucosal tunnelling endoscopic resection Gastrointestinal tract

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

MXR7 facilitates liver cancer metastasis via epithelial-mesenchymal transition

引用

Science china(Life Sciences) 2017年第11期60卷 1203-1213页

作者： guishuai lv yexiong tan hongwei lv tian fang changzheng wang ting li yanting yu congli hu wen wen hongyang wang wen yang international cooperation laboratory on signal transduction eastern hepatobiliary surgery institutesecond military medical universityShanghai 200438China national center for liver cancer Shanghai 201805China state key laboratory of oncogenes and related genes shanghai cancer institute renji hospitalshanghai jiaotong university school of medicineShanghai 200127China

MXR7 is a cell-surface protein and highly expressed in hepatocellular carcinoma(HCC). The aim of this study is to determine the expression profile of MXR7 in HCC and investigate the influence of MXR7 on invasion and metastasis of HCC cells. For this purpose, immunohistochemical assay was used to identify the differential expression of MXR7 in 94 HCC specimens. Expression of MXR7 in 4 pairs of HCC and portal vein tumor thrombus(PVTT) was also tested. The motility of HCC cells were characterized by transwell migration and matrigel invasion assays. In vivo metastasis potential was determined via tail vein injection ***, compared with noninvasive HCC tumors or human HCC cell lines with low metastatic potential, invasive HCC samples and HCC cell lines with high metastatic potential exhibited higher MXR7 expression. Furthermore, forced expression of MXR7 in SMMC-7721 promoted cell proliferation, migration and invasion in vitro and accelerated tumor growth and metastasis in vivo. Conversely, knockdown of MXR7 expression in HuH7 cells inhibited proliferation and motility of cells. Mechanically,overexpression of MXR7 promoted epithelial-mesenchymal transition(EMT) progress, and MXR7 depletion repressed the EMT phenotype. In conclusion, MXR7 is a mediator of EMT and metastasis in HCC and may serve as a novel therapeutic target.

关键词： hepatocellular carcinoma(HCC) MXR7 metastasis epithelial-mesenchymal transition(EMT)

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Treatment of cholecystitis with Chinese herbal medicines:A systematic review of the literature

引用

World Journal of Gastroenterology 2012年第14期18卷 1689-1694页

作者： Zhi-Yong Dong Guan-Liang wang xing Liu Jia Liu De-Zeng Zhu Chang-Quan ling department of hepatobiliary Surgery Affiliated Hospital of Pu Tian UniversityPutian 351100Fujian ProvinceChina department of Traditional Chinese medicine Changhai Hospital affiliated to the Second Military Medical UniversityShanghai 200433China Center for the Study of Language and Cognition Zhe-jiang University Hangzhou 310028 Zhejiang Province China Yueyang hospital of Integrated Traditional Chinese andWestern medicine Shanghai University of Traditional ChineseMedicine Shanghai 200437 China

AIM:To analyze the literature on the use of Chinese herbal medicines for the treatment of ***:The literature on treatment of cholecystitis with traditional Chinese medicines(TCM) was analyzed based on the principles and methods described by evidence-based medicine(EBM).Eight databases including MEDLINE,EMbase,Cochrane Central(CCTR),four Chinese databases(china Biological medicineDatabase,Chinese National Knowledge Infrastructure Database,Database of Chinese Science and Technology Periodicals,Database of Chinese Ministry of Science and Technology) and Chinese Clinical Registry Center,were *** text articles or abstracts concerning TCM treatment of cholecystitis were selected,categorized according to study design,the strength of evidence,the first author's hospital type,and analyzed ***:A search of the literature published from 1977 through 2009 yielded 1468 articles in Chinese and 9 in other languages;and 93.92% of the articles focused on clinical *** article was of levelⅠevidence,and 9.26% were of level Ⅱ *** literature cited by Science Citation Index(SCI),MEDLINE and core Chinese medical journals accounted for 0.41%,0.68% and 7.29%,***,the articles featured in case reports of illness,examined from the perspective of EBM,were weak in both quality and evidence level,which inconsistently conflicted with the fact that most of the papers were by authors from Level-3 hospitals,the highest possible level evaluated based on their comprehensive quality and academic authenticity in ***:The published literature on TCM treatment of cholecystitis is of low quality and based on low evidence,and cognitive medicine may functions as a useful supplementary framework for the evaluation.

关键词： Cholecystitis Traditional Chinese medicine Literature analysis Randomized controlled trials Cognition-based medicine

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：